Arrowhead Pharmaceuticals (ARWR) said Monday that it submitted a new drug application to the US Food and Drug Administration for its experimental drug, plozasiran, to treat familial chylomicronemia syndrome, a rare disease that could lead to potentially fatal pancreatitis.
The company said the application is supported by data from a phase 3 study that met primary and key secondary endpoints, including reductions in triglycerides and the incidence of acute pancreatitis.
The drugmaker also said it plans to seek approval for plozasiran from other regulatory authorities in 2025.
Shares of the company were up more than 3% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。